Iron treatment: impact of safety issues.

Improved outcomes result when a hemodialysis patient's hematocrit is increased to greater then 33%. The recent National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) Anemia Panel recommended the use of intravenous (i.v.) iron therapy to increase hematocrits into this range. As the use of i.v. iron has increased, there has been an interest in more critically assessing the potential risks of such therapy. In this article, the possible risks are reviewed and considered in concert with the known benefits of iron treatment. A recommendation is made, in contrast to the NKF-DOQI Guidelines, that i.v. iron should not be administered to hemodialysis patients if the serum ferritin level if greater than 500 ng/mL.

• Publication year

  1998

• Venue

  American Journal of Kidney Diseases

• Publication date

  1998-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0272-6386(98)70179-9PMID 9892383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disorders of iron metabolism.

  1999cited by this paper
• EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients.

  1998cited by this paper
• Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.

  1998cited by this paper
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper
• Association between body iron stores and the risk of acute myocardial infarction in men.

  1998cited by this paper
• Iron status and risk of cardiovascular disease.

  1997cited by this paper
• Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis.

  1997cited by this paper
• The safety of intravenous iron dextran in hemodialysis patients.

  1996cited by this paper
• Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey.

  1995cited by this paper
• Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.

  1995cited by this paper
• Dietary iron intake and risk of coronary disease among men.

  1994cited by this paper
• Iron poisoning in children

  1994cited by this paper
• A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.

  1992cited by this paper
• Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.

  1992cited by this paper
• High Stored Iron Levels Are Associated With Excess Risk of Myocardial Infarction in Eastern Finnish Men

  1992cited by this paper
• Structure/histotoxicity relationship of parenteral iron preparations.

  1992cited by this paper
• [Yersinia enterocolitica septicemia associated with idiopathic hemochromatosis and deferoxamine therapy. A case].

  1991cited by this paper
• Is iron sufficiency a risk factor in ischemic heart disease?

  1991cited by this paper
• The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin

  1990cited by this paper
• The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group.

  1990cited by this paper
• Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine.

  1989cited by this paper
• Efficiency of chelated iron compounds as catalysts for the Haber-Weiss reaction.

  1985cited by this paper
• Relationship of iron and extracellular virulence factors to Pseudomonas aeruginosa lung infections.

  1984cited by this paper
• Intravenous iron dextran in clinical medicine.

  1980cited by this paper
• Dextran-induced anaphylactoid reactions. Report of two cases.

  1974cited by this paper
• The abolition of the protective effect of Pasteurella septica antiserum by iron compounds.

  1968cited by this paper

• The Value of Intravenous Iron: Beyond the Cave of Speculation.

  2020cites this paper
• Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease

  2012cites this paper
• Anemia in PD Patients

  2009cites this paper
• Tratamiento de la anemia con eritropoietina y hierro en Enfermedad Renal Crónica

  2008cites this paper
• Anemia in children with chronic kidney disease

  2007cites this paper
• Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

  2007cites this paper
• How to optimise anaemia therapy in peritoneal dialysis patients.

  2006cites this paper
• [Resorption and tolerance of the high doses of ferrous sulfate and ferrous gluconate in the patients on peritoneal dialysis].

  2006cites this paper
• Iron therapy in the pediatric hemodialysis population

  2004cites this paper
• Update on parenteral iron therapy.

  2003cites this paper
• Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients.

  2002cites this paper
• Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease.

  2002cites this paper
• Experience with a Large Dose (500 MG) of Intravenous Iron Dextran and Iron Saccharate in Peritoneal Dialysis Patients

  2001cites this paper
• Serum ferritin is a marker of morbidity and mortality in hemodialysis patients.

  2001cites this paper
• Parenteral iron use in the management of anemia in end-stage renal disease patients.

  2000cites this paper
• Anemia na insuficiência renal crônica: novas tendências

  1999cites this paper
• Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond.

  1999cites this paper